Efficacy of Sequential Therapy as the First-Line Treatment in the Eradication of Helicobacter pylori

被引:0
|
作者
Tamene, Yonas [1 ]
Mody, Shefali P. [2 ]
Sadiq, Kaiser O. [3 ]
Shivakumar, Yogamba M. [2 ]
Burra, Eshwar [4 ]
Shahid, Kamran [5 ]
Nath, Tuheen Sankar [6 ]
机构
[1] Calif Inst Behav Neurosci & Psychol, Internal Med, Fairfield, CA 94534 USA
[2] Calif Inst Behav Neurosci & Psychol, Med, Fairfield, CA USA
[3] Plexus Neuro & Stem Cell Res Ctr, Surg, Bangalore, India
[4] Govt Med Coll, Internal Med, Nizamabad, India
[5] Calif Inst Behav Neurosci & Psychol, Internal Med Family Med, Fairfield, CA USA
[6] Calif Inst Behav Neurosci & Psychol, Clin Res, Fairfield, CA USA
关键词
h. pylori eradication; h; pylori; h. pylori infection; helicobacter pylori; h. pylori antibotic; 7-DAY TRIPLE THERAPY; TRIAL; CONCOMITANT; INFECTION; SUPERIOR; REGIMEN;
D O I
10.7759/cureus.45593
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Helicobacter pylori infection is a significant issue in global health as it is associated with a range of gastrointestinal disorders and an elevated likelihood of developing stomach cancer. The declining efficacy of standard triple therapy (TT) as the recommended treatment can be attributed to the emergence of drug resistant strains. Sequential therapy (ST) has been recognized as an alternative approach, wherein a combination of proton-pump inhibitor (PPI) and amoxicillin is administered for the initial five days, followed by a combination of PPI, clarithromycin, and metronidazole for the subsequent five days. In this comprehensive systematic review and meta-analysis, we have thoroughly assessed the effectiveness and tolerability of ST as a primary treatment option in comparison to TT for the eradication of H. pylori. The analysis comprised a total of 15 randomized controlled trials, encompassing a sample size of 5,219 patients. The collective findings indicate that ST exhibits promise as it achieves higher rates of eradication. Additionally, it is worth noting that this approach has the potential to yield cost savings and enhance treatment compliance when compared to TT. To summarize, this systematic review and meta-analysis provide evidence that ST is a viable option for the initial treatment of H. pylori eradication. It shows potential benefits compared to the standard TT, especially when there is resistance to clarithromycin. In order to establish ST as the preferred first-line treatment, it is imperative that additional research be conducted to address the aforementioned limitations and thoroughly investigate its long-term efficacy and safety profiles. Nevertheless, it is required that additional research be conducted in order to adequately tackle the constraints of the current studies and solidify its position as a favored treatment alternative. It is also essential to consider ST as a viable approach to improve the rates of H. pylori eradication. This method should be thoroughly examined in clinical practice to gain a deeper understanding of its effectiveness.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] First-line triple therapy with levofloxacin for Helicobacter pylori eradication
    Gisbert, J. P.
    Fernandez-Bermejo, M.
    Molina-Infante, J.
    Perez-Gallardo, B.
    Prieto-Bermejo, A.-B.
    Mateos-Rodriguez, J.-M.
    Robledo-Andres, P.
    Gonzalez-Garcia, G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) : 495 - 500
  • [22] Efficacy of First-Line Helicobacter pylori Eradication Treatment With Two Triple Regimens With Levofloxacin
    Trespalacios, Alba A.
    Otero, William
    Marcela, Mercado
    GASTROENTEROLOGY, 2014, 146 (05) : S741 - S742
  • [23] The efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy
    Oh, Dong Hyun
    Lee, Dong Ho
    Kang, Kyu Keun
    Park, Young Soo
    Shin, Cheol Min
    Kim, Nayoung
    Yoon, Hyuk
    Hwang, Jin Hyeok
    Jeoung, Sook Hyang
    Kim, Jin Wook
    Jang, Eun Sun
    Jung, Hyun Chae
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (06) : 1171 - 1176
  • [24] Comparing efficacy of Helicobacter pylori eradication regimens: Bismuth containing quintet therapy vs moxifloxacin based sequential therapy as first-line eradication regimen
    Kim, Y.
    Lee, D.
    Shin, C.
    Yoon, H.
    Park, Y.
    Kim, N.
    HELICOBACTER, 2020, 25 : 11 - 11
  • [25] Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication
    Nista, Enrico C.
    Candelli, Marcello
    Zocco, Maria A.
    Cremonini, Filippo
    Ojetti, Veronica
    Finizio, Rosalba
    Spada, Cristiano
    Cammarota, Giovanni
    Gasbarrini, Giovanni
    Gasbarrini, Antonio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : 1985 - 1990
  • [26] An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility
    Miyaki, Akira
    Yamaguchi, Kentaro
    Ida, Arika
    Miyauchi, Tatsuomi
    MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2016, 62 (03) : 234 - 239
  • [27] Triple therapy versus concomitant therapy for the first-line Helicobacter pylori eradication
    Lee, M.
    Kim, G.
    Lee, B.
    Jeon, H.
    Park, E.
    Song, G.
    HELICOBACTER, 2017, 22
  • [28] First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic
    Ozbalci, Gokhan Selcuk
    Yuruker, Saim Savas
    Tarim, Ismail Alper
    Cinar, Hamza
    Polat, Ayfer Kamali
    Ozbalci, Aysu Basak
    Karabulut, Kagan
    Erzurumlu, Kenan
    TURKISH JOURNAL OF SURGERY, 2014, 30 (03) : 133 - 137
  • [29] Sequential versus concomitant non-bismuth quadruple therapy as first-line eradication for helicobacter pylori
    Pereira, F.
    Azevedo, R.
    Linhares, M.
    Ramos, D.
    Pinto, J.
    Caldeira, A.
    Tristan, J.
    Pereira, E.
    Sousa, R.
    Banhudo, A.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2019, 31
  • [30] Sequential Therapy for First-Line Helicobacter pylori Eradication: 10-or 14-Day Regimen?
    Zullo, Angelo
    Fiorini, Giulia
    Scaccianoce, Giuseppe
    Portincasa, Piero
    De Francesco, Vincenzo
    Vassallo, Roberto
    Urban, Flavia
    Monica, Fabio
    Mogavero, Giuseppe
    Amato, Arnaldo
    Vaira, Dino
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2019, 28 (01) : 11 - 14